These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7940732)

  • 1. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study.
    Farges O; Ericzon BG; Bresson-Hadni S; Lynch SV; Höckerstedt K; Houssin D; Galmarini D; Faure JL; Baldauf C; Bismuth H
    Transplantation; 1994 Oct; 58(8):891-8. PubMed ID: 7940732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKT3 prophylaxis in liver transplantation.
    McDiarmid SV; Millis MJ; Terasaki PI; Ament ME; Busuttil RW
    Dig Dis Sci; 1991 Oct; 36(10):1418-26. PubMed ID: 1833167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.
    Benfield MR; Tejani A; Harmon WE; McDonald R; Stablein DM; McIntosh M; Rose S;
    Pediatr Transplant; 2005 Jun; 9(3):282-92. PubMed ID: 15910382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with OKT3 in pediatric liver-transplant recipients.
    Ryckman FC; Schroeder TJ; Pedersen SH; Dittrich VS; Balistreri WF
    Transplant Sci; 1994 Dec; 4 Suppl 1():S20-5. PubMed ID: 7627451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OKT3 prophylaxis in liver transplant patients: a European and Australian multicenter, prospective controlled trial.
    Höckerstedt K; Ericzon BG; Bismuth H; Chapuis Y; Farges O; Faure JL; Galmarini D; Houssin D; Lynch SV; Miguet J
    Transplant Proc; 1993 Feb; 25(1 Pt 1):556-7. PubMed ID: 8438412
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
    Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
    Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation.
    Wall WJ; Ghent CN; Roy A; McAlister VC; Grant DR; Adams PC
    Dig Dis Sci; 1995 Jan; 40(1):52-7. PubMed ID: 7821119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low-dose OKT3 as induction therapy in liver transplantation.
    Whiting JF; Fecteau A; Martin J; Bejarano PA; Hanto DW
    Transplantation; 1998 Feb; 65(4):577-80. PubMed ID: 9500637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive OKT3 treatment with cyclosporine (Sandimmun) for second kidney transplantation.
    Perner F; Alföldy F; Járay J; Hidvégi M; Hemangshu P
    Transpl Int; 1994; 7 Suppl 1():S255-8. PubMed ID: 11271218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Reding R; Vraux H; de Ville de Goyet J; Sokal E; de Hemptinne B; Latinne D; Rahier J; Jamart J; Vincenzotto C; Cormont F
    Transplantation; 1993 Mar; 55(3):534-41. PubMed ID: 8456474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival.
    Abramowicz D; Norman DJ; Vereerstraeten P; Goldman M; De Pauw L; Vanherweghem JL; Kinnaert P; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Wu SC; Haverty TP
    Kidney Int; 1996 Mar; 49(3):768-72. PubMed ID: 8648918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
    Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction with OKT3 and prostaglandin E1 in liver transplantation.
    Fisher RA; Posner M; Shiffman ML; Wolfe L; Lee HM
    Transplant Sci; 1994 Dec; 4 Suppl 1():S1-8. PubMed ID: 7627450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
    Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
    Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
    [No Abstract]   [Full Text] [Related]  

  • 18. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.
    Millis JM; McDiarmid SV; Hiatt JR; Brems JJ; Colonna JO; Klein AS; Ashizawa T; Hart J; Lewin K; Goldstein LI
    Transplantation; 1989 Jan; 47(1):82-8. PubMed ID: 2521409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction.
    Sheiner PA; Guarrera JV; Grunstein E; Emre S; Guy SR; Schwartz ME; Miller CM; Boros P
    Transplantation; 1997 Oct; 64(8):1214-6. PubMed ID: 9355846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.